reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

AIxCrypto Holdings, Inc.

AIXC · Nasdaq

1 reporting failure in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.

$6Mpublic float
2025-12-16most recent failure

Score over time

0123202220232024202520262023-04-01 · score 12023-03-31 filed late (10-K)2023-07-01 · score 12023-03-31 filed late (10-K)2023-10-01 · score 12023-03-31 filed late (10-K)2024-01-01 · score 12023-03-31 filed late (10-K)2024-07-01 · score 22024-05-14 filed late (10-Q) · accounts not ready2024-04-01 filed late (10-K) · auditor2024-10-01 · score 32024-07-15 auditor change2024-05-14 filed late (10-Q) · accounts not ready2024-04-01 filed late (10-K) · auditor2025-01-01 · score 32024-07-15 auditor change2024-05-14 filed late (10-Q) · accounts not ready2024-04-01 filed late (10-K) · auditor2025-04-01 · score 32024-07-15 auditor change2024-05-14 filed late (10-Q) · accounts not ready2024-04-01 filed late (10-K) · auditor2025-07-01 · score 22025-04-01 filed late (10-K) · accounts not ready2024-07-15 auditor change2025-10-01 · score 12025-04-01 filed late (10-K) · accounts not ready2026-01-01 · score 32025-12-16 auditor change2025-10-07 auditor change2025-04-01 filed late (10-K) · accounts not ready2026-04-01 · score 32025-12-16 auditor change2025-10-07 auditor change2025-04-01 filed late (10-K) · accounts not ready2026-07-01 · score 22025-12-16 auditor change2025-10-07 auditor change2026-10-01 · score 22025-12-16 auditor change2025-10-07 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

The Registrant could not complete the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) due to a delay in obtaining and compiling information required to be included in the Form 10-K, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Registrant will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date

NT 10-K, filed 2025-04-01 · accounts not ready

What it filed

2025-12-16auditor changed or resigned SEC →

2025-10-07auditor changed or resigned SEC →

2025-04-01filed late (10-K)accounts not ready SEC →

The Registrant could not complete the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) due to a delay in obtaining and compiling information required to be included in the Form 10-K, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Registrant will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date

2024-07-15auditor changed or resigned SEC →

2024-05-14filed late (10-Q)accounts not ready SEC →

This Form 12b-25 (Notification of Late Filing) is being filed by Qualigen Therapeutics, Inc. (the “ Company ”) to seek an extension of the filing deadline for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 pursuant to Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended. The due date for the filing of the Quarterly Report is May 15, 2024. Qualigen Therapeutics, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Form 10-Q”) within the prescribed time period. The Company requires additional time to complete the accounting and disclosures related to the Company’s transactions regarding Alpha Capital Anstalt. The Company currently expects that it will be able to complete the necessary work to file the Form 10-Q within the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended

2024-04-01filed late (10-K)auditor SEC →

This Form 12b-25 (Notification of Late Filing) is being filed by Qualigen Therapeutics, Inc. (the “ Company ”) to seek an extension of the filing deadline for its Annual Report on Form 10-K for the year ended December 31, 2023 (the “ Annual Report ”) pursuant to Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended. The due date for the filing of the Annual Report is April 1, 2024. Qualigen Therapeutics, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) within the prescribed time period. The Company and its registered public accounting firm require additional time to complete the accounting and disclosures related to the Company’s transactions regarding Alpha Capital Anstalt, NanoSynex, Ltd. and Qualigen, Inc. The Company currently expects that it will be able to complete the necessary work to file the Form 10-K within the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended

2023-03-31filed late (10-K) SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com